Should I Take Wegovy for Weight Loss? What the Evidence Actually Says

The biggest misconception: that Wegovy is a shortcut rather than a clinical treatment

One of the most common things people believe about weight-loss medicines is that they do the work instead of you, that you keep eating the same way and the drug takes over. It's a natural assumption, and letting it go changes how you think about the decision. Wegovy works by reducing appetite and slowing gastric emptying, which makes sticking to a lower-calorie pattern far more manageable. But Wegovy is licensed for use alongside a reduced-calorie diet and increased physical activity, not as a replacement for them. The clinical trials were conducted in people who also made lifestyle changes. Thinking of it as a tool that lowers one of the biggest barriers (persistent hunger) is more accurate than thinking of it as a passive fix. That distinction matters when you're weighing whether Wegovy is genuinely right for your situation, because the results people experience are shaped by what they do alongside the medicine.

The STEP 1 trial, published in the New England Journal of Medicine, reported roughly 15% average body weight reduction over 68 weeks at the 2.4 mg maintenance dose. Those are meaningful results, but they come from a structured programme, not a standalone injection.

Who the licensed eligibility criteria actually cover

Wegovy is licensed in the UK for adults. The two qualifying routes are: a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related health condition. Conditions that commonly qualify include high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea, and osteoarthritis, among others. Thresholds are typically set 2.5 kg/m² lower for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, in line with UK guidance.

Meeting the BMI threshold is a starting point, not a guarantee. Wegovy is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for people under 18. Certain medical histories (including a personal or family history of medullary thyroid carcinoma, or a condition called MEN2) rule it out, as do some other conditions. Medicines you already take matter too: your prescriber will review everything. If you're unsure where you stand, our guide to deciding whether to go on Wegovy walks through the key questions to consider before having that clinical conversation. If you're thinking through whether you should take Wegovy given your personal circumstances, that decision should always involve a real clinical conversation, not a checklist.

If you're exploring treatment options more broadly, our weight-loss overview sets out what's licensed in the UK and how the different approaches compare.

Side effects: what to expect and when to seek help

The most commonly reported side effects with Wegovy are gastrointestinal, nausea, loose stools, constipation, indigestion, and burping are the ones patients mention most. These tend to be at their most noticeable after starting and after each dose increase, and they often settle within a couple of weeks as your body adjusts. The gradual titration schedule exists partly for this reason: moving up in small steps gives your system time to adapt.

Less common but more serious effects require prompt attention. Severe, persistent abdominal pain (particularly if it radiates toward the back) should be assessed urgently, as pancreatitis is a known, if infrequent, risk with GLP-1 medicines. The MHRA's Yellow Card scheme allows patients to report any suspected side effects directly. Gallbladder problems, signs of a serious allergic reaction, and symptoms of significant dehydration after prolonged vomiting or diarrhoea are all reasons to contact a doctor without delay.

Side effects affect people differently. Some find the first few weeks straightforward; others find them harder. Understanding that the titration pace is there to help (not to slow things down arbitrarily) can make that period feel more manageable. For more on how Wegovy is taken, including what the dose schedule looks like in practice, our dedicated page covers the full picture. Practical questions such as whether to take your dose at night or at another time of day can also make a difference to how well you tolerate the medicine.

NHS access versus private treatment: the practical reality

NICE recommends semaglutide (Wegovy) on the NHS only within specialist weight management services, for a maximum of two years, for people with a BMI of 35 or above and at least one weight-related condition, with lower thresholds for some ethnic backgrounds. In practice, NHS access is subject to referral criteria and waiting lists that can be considerable. NICE's technology appraisal TA875 sets out the full NHS commissioning conditions.

Private treatment through a regulated online pharmacy is an option for people who don't meet NHS criteria, can't access it locally, or prefer not to wait. The key question is whether the pharmacy is properly regulated: it should be registered with the GPhC, dispense through the licensed UK supply chain, and require a genuine clinical assessment (not just a quick online form) before supplying a prescription-only medicine. You can verify any online pharmacy on the GPhC register. Pharmacies offering Wegovy without a proper clinical review are a safety concern, not a convenience.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber the same day, a clinician reads your answers, not automated software. If you'd like to understand whether you might be suitable, checking your eligibility through a free consultation is the right first step.